Brandon A Francis1, Jennifer Fillenworth2, Philip Gorelick3, Kristina Karanec2, Adriana Tanner2. 1. Neurocritical Care, Hauenstein Neurosciences Mercy Health Saint Mary's, 200 Cherry Street, Grand Rapids, MI, 49503, USA. Brandon.francis@mercyhealth.com. 2. Epilepsy Center, Hauenstein Neurosciences Mercy Health Saint Mary's, Grand Rapids, MI, USA. 3. Vascular Neurology, Hauenstein Neurosciences Mercy Health Saint Mary's, Grand Rapids, MI, USA.
Abstract
BACKGROUND: Status, refractory status and super refractory status epilepticus are common neurologic emergencies. The objective of this study is to investigate the feasibility, safety and effectiveness of a ketogenic diet (KD) for refractory status epilepticus (RSE) in adults in the intensive care unit (ICU). METHODS: We performed a retrospective, single-center study of patients between ages 18 and 80 years with RSE treated with a KD treatment algorithm from November 2016 through April 2018. The primary outcome measure was urine ketone body production as a biomarker of feasibility. Secondary measures included resolution of RSE and KD-related side effects. RESULTS: There were 11 adults who were diagnosed with RSE that were treated with the KD. The mean age was 48 years, and 45% (n = 5) of the patients were women. The patients were prescribed a median of three anti-seizure medications before initiating the KD. The median duration of RSE before initiation of the KD was 1 day. Treatment delays were the result of Propofol administration. 90.9% (n = 10) of patients achieved ketosis within a median of 1 day. RSE resolved in 72.7% (n = 8) of patients; however, 27.3% (n = 3) developed super-refractory status epilepticus. Side effects included metabolic acidosis, hypoglycemia and hyponatremia. One patient (20%) died. CONCLUSIONS: KD may be feasible, safe and effective for treatment of RSE in the ICU. A randomized controlled trial (RCT) may be indicated to further test the safety and efficacy of KD.
BACKGROUND: Status, refractory status and super refractory status epilepticus are common neurologic emergencies. The objective of this study is to investigate the feasibility, safety and effectiveness of a ketogenic diet (KD) for refractory status epilepticus (RSE) in adults in the intensive care unit (ICU). METHODS: We performed a retrospective, single-center study of patients between ages 18 and 80 years with RSE treated with a KD treatment algorithm from November 2016 through April 2018. The primary outcome measure was urine ketone body production as a biomarker of feasibility. Secondary measures included resolution of RSE and KD-related side effects. RESULTS: There were 11 adults who were diagnosed with RSE that were treated with the KD. The mean age was 48 years, and 45% (n = 5) of the patients were women. The patients were prescribed a median of three anti-seizure medications before initiating the KD. The median duration of RSE before initiation of the KD was 1 day. Treatment delays were the result of Propofol administration. 90.9% (n = 10) of patients achieved ketosis within a median of 1 day. RSE resolved in 72.7% (n = 8) of patients; however, 27.3% (n = 3) developed super-refractory status epilepticus. Side effects included metabolic acidosis, hypoglycemia and hyponatremia. One patient (20%) died. CONCLUSIONS: KD may be feasible, safe and effective for treatment of RSE in the ICU. A randomized controlled trial (RCT) may be indicated to further test the safety and efficacy of KD.
Entities:
Keywords:
Ketogenic diet; Neurocritical care; Refractory status epilepticus
Authors: Mackenzie C Cervenka; Sara Hocker; Matthew Koenig; Barak Bar; Bobbie Henry-Barron; Eric H Kossoff; Adam L Hartman; John C Probasco; David R Benavides; Arun Venkatesan; Eliza C Hagen; Denise Dittrich; Tracy Stern; Batya Radzik; Marie Depew; Filissa M Caserta; Paul Nyquist; Peter W Kaplan; Romergryko G Geocadin Journal: Neurology Date: 2017-02-08 Impact factor: 9.910
Authors: Kiran T Thakur; John C Probasco; Sara E Hocker; Kelly Roehl; Bobbie Henry; Eric H Kossoff; Peter W Kaplan; Romergryko G Geocadin; Adam L Hartman; Arun Venkatesan; Mackenzie C Cervenka Journal: Neurology Date: 2014-01-22 Impact factor: 9.910
Authors: M Leitinger; S Beniczky; A Rohracher; E Gardella; G Kalss; E Qerama; J Höfler; A Hess Lindberg-Larsen; G Kuchukhidze; J Dobesberger; P B Langthaler; E Trinka Journal: Epilepsy Behav Date: 2015-06-17 Impact factor: 2.937
Authors: Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa Journal: Neurocrit Care Date: 2012-08 Impact factor: 3.210
Authors: Mackenzie C Cervenka; Susan Wood; Manny Bagary; Antoaneta Balabanov; Eduard Bercovici; Mesha-Gay Brown; Orrin Devinsky; Cherubino Di Lorenzo; Colin P Doherty; Elizabeth Felton; Laura A Healy; Pavel Klein; Magnhild Kverneland; Danielle Lambrechts; Jennifer Langer; Janak Nathan; Jude Munn; Patty Nguyen; Matthew Phillips; Kelly Roehl; Adrianna Tanner; Clare Williams; Beth Zupec-Kania Journal: Neurol Clin Pract Date: 2021-10
Authors: Markus Breu; Chiara Häfele; Sarah Glatter; Petra Trimmel-Schwahofer; Johann Golej; Christoph Male; Martha Feucht; Anastasia Dressler Journal: Front Neurol Date: 2021-06-03 Impact factor: 4.003
Authors: Alexis N Simpkins; Katharina M Busl; Edilberto Amorim; Carolina Barnett-Tapia; Mackenzie C Cervenka; Monica B Dhakar; Mark R Etherton; Celia Fung; Robert Griggs; Robert G Holloway; Adam G Kelly; Imad R Khan; Karlo J Lizarraga; Hannah G Madagan; Chidinma L Onweni; Humberto Mestre; Alejandro A Rabinstein; Clio Rubinos; Dawling A Dionisio-Santos; Teddy S Youn; Lisa H Merck; Carolina B Maciel Journal: Neurocrit Care Date: 2020-09-21 Impact factor: 3.210
Authors: Juan G Ochoa; Michelle Dougherty; Alex Papanastassiou; Barry Gidal; Ismail Mohamed; David G Vossler Journal: Epilepsy Curr Date: 2021-03-10 Impact factor: 7.500